髓系肿瘤（MN）属于一组以造血干祖细胞生物学功能异常为特征的血液系统恶性肿瘤。 MN患者异常的免疫和造血微环境与恶性克隆造血干细胞相互作用，促进其疾病的发生和发展。 MN大颗粒淋巴细胞增殖（MN-LGLP）是此类疾病中一种特殊且罕见的临床现象。目前，国内外对该疾病的研究还很有限。本研究分析了该类患者的临床和实验室特征，探讨LGLP对MN患者临床特征和生存的影响。 MN-LGLP 患者容易出现中性粒细胞减少和脾肿大。 LGLP 的存在并不是影响 MN-LGLP 患者生存的危险因素。 STAG、ASXL1和TET2是MN-LGLP最常见的伴随基因突变，MN-LGLP和STAG2突变的患者预后较差。

Myeloid neoplasms (MNs) belong to a group of hematological malignancies characterized by the abnormal biological functions of hematopoietic stem progenitor cells. The abnormal immune and hematopoietic microenvironment of patients with MN interact with malignant clonal hematopoietic stem cells, promoting the occurrence and development of their diseases. MN large granular lymphocyte proliferation (MN-LGLP) is a special and rare clinical phenomenon in this type of disease. Currently, research on this disease in domestic and international cohorts is limited. This study analyzes the clinical and laboratory characteristics of this type of patient and explores the impact of LGLP on the clinical characteristics and survival of patients with MN. Patients with MN-LGLP are prone to neutropenia and splenomegaly. The presence of LGLP is not a risk factor affecting the survival of patients with MN-LGLP. STAG, ASXL1, and TET2 are the most common accompanying gene mutations in MN-LGLP, and patients with MN-LGLP and STAG2 mutations have poor prognoses.